This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Non-small cell lung cancer (NSCLC)	NK2 homeobox 1 (NKX2-1; TTF1); NKX2-8	<p><i>In vitro</i> studies suggest that gene expression profiles of TTF1 and NKX2-8 could be used for patient prognosis and prediction of cisplatin resistance in NSCLC. In human bronchial epithelial cells transfected with <i>TTF1</i> and <i>NKX2-8</i>, gene expression profiles showed that coactivation of the TTF1 and NKX2-8 pathways in primary tumors could identify patients with poor prognosis. Coactivation of <i>TTF1</i> and <i>NKX2-8</i> pathways in lung cancer cell lines also correlated with resistance to cisplatin therapy, the standard of care for NSCLC. Next steps could include <i>in vivo</i> studies to validate the findings. Eleven companies have therapies marketed or approved to treat NSCLC.</p> <p>At least 25 companies have therapies in Phase III testing to treat NSCLC.</p> <p>SciBX 2(11); doi:10.1038/scibx.2009.445 Published online March 19, 2009</p>	Patent and licensing status undisclosed	<p>Hsu, D. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online March 9, 2009; doi:10.1073/pnas.0900827106</p> <p>Contact: Anil Potti, Duke University, Durham, N.C. e-mail: anil.potti@duke.edu</p>